DJO, ReAble merger hits lawsuit snag:
This article was originally published in Clinica
Executive Summary
A class action lawsuit claiming that DJO shareholders have been left high and dry by the company's proposed merger with ReAble Therapeutics could scupper the $1.6bn bid. The complaint alleges that the deal, which has already received the go-ahead from the US Federal Trade Commission (see Clinica No 1270, p 13), was inadequately priced and breached DJO's fiduciary duty to seek a transaction that would provide shareholders with optimum value. The action calls for an injunction on the merger and monetary damages. DJO said the lawsuit is without merit and will vigorously oppose it. However, the Vista, California company added that it expects further similar lawsuits to be filed.
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.